GLPwatch
Papers (10588)
Page 170 of 177, ranked by citation count.
- Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
- Anti-obesity compounds, Semaglutide and LiPR, and PrRP do not change the proportion of human and mouse POMC+ neurons.
- Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study.
- Reply.
- Weight "regain" in obesity shifts responsibility from biology to personal inadequacy.
- In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.
- Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Prompting a Meaningful Improvement in Alcohol Use Disorder.
- [Pharmacotherapy for obesity].
- Effects of lixisenatide treatment on mild cachexia and related metabolic abnormalities in Walker-256 tumour-bearing rats.
- Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing.
- Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus: a network meta-analysis based on clinical trials.
- Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.
- Switch from premixed insulin analogue to degludec-liraglutide combination: a CGM study.
- Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis.
- An analysis of dosage volume for halfway doses in the Victoza Pen.
- The role of combination therapy in type 2 diabetes in the post-ACCORD era.
- A glucose-responsive dual-nanoparticle-hydrogel-based microneedle patch for co-delivery of insulin and exendin-4.
- [Cardiovascular aspects of diabetes treatment : Finally a reason for cardiologists to be pleased].
- Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance.
- Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management.
- [Case report: successful treatment with liraglutide in an insulin allergic patient with liver cirrhosis, hepatocellular carcinoma and poor glycemic control using high dose of insulin].
- Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts.
- Targeting UBE2B-mediated U2AF1 degradation to alleviate endothelial dysfunction in renal ischemia-reperfusion injury: therapeutic potential of semaglutide.
- Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
- [Optimizing treatment of type 2 diabetic patients].
- Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections.
- Comparative Effectiveness of Liraglutide versus Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Multicenter Propensity Score-Matched Real-World Study.
- Letter by Ma et al Regarding Article, "Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial".
- A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
- Comparative analysis of LJ-4378 and tirzepatide in mouse models of obesity and weight regain.
- ICER report demonstrates both the value and challenges in financing of weight loss medications.
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.
- Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
- Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.
- Liraglutide Nano-Preparation on Perioperative Neurocognitive Dysfunction in Aged Mice.
- Iixisenatide. Wait for conclusive results on complications of diabetes.
- Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations.
- Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes.
- [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER].
- Diabetes News.
- Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence.
- Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides.
- Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial.
- Response to "Effects of semaglutide on cardiovascular risk factors and eating behaviors in type 2 diabetes".
- Can early use of insulin, GLP-1 halt diabetes progression?
- Combination therapy of GLP-1 analogues and insulin: do the benefits outweigh the costs?
- Exendin-4 alleviates Aβ1-40-induced apoptosis and calcium dysregulation in RPE cells through the CHP1/NHE1 complex.
- dulaglutide (Trulicity°) weekly in type 2 diabetes: Cardiovascular reactions should be better documented.
- [The renal protective effect and mechanism of liraglutide in diabetic mice induced by high-fat diet].
- Exenatide challenge in oral glucose tolerance test is insufficient for predictions of glucose metabolism and insulin secretion after sleeve gastrectomy (SG) in obese patients with type 2 diabetes: a pilot study to establish a preoperative model to estimate β-cell function following augmented glucagon-like peptide-1 secretion after SG.
- [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
- In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than oral semaglutide at 52 wk.
- Effects of GLP1 receptor analogues in obesity with neurodevelopmental disorder: case report of a patient with holoprosencephaly.
- [Liraglutide in the treatment of obesity : a multidisciplinary approach].
- [Liraglutide for weight loss in overweight and obese adults].
- Differential Biliary Adverse Event Signals Among Glp-1 Receptor Agonists: A FAERS Disproportionality Analysis.
- COMBINE 2 is better than one: shaping the future of therapeutics in inadequately controlled type 2 diabetes.
- Lixisenatide for type 2 diabetes.
- New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.